English	French	Notes	Complete/Exclude
       EVIDENCE OF METASTASIS......: Not documented			
1402 11. DATE OF FIRST TISSUE DIAGNOSIS			
 12. DISTANCE IN MILLIMETERS TO CLOSEST MARGIN:			
1429      PROXIMAL MARGIN..............			
1429.1      DISTAL MARGIN................			
1417 13. FROZEN SECTION................			
1418.3      CHEST WALL...................			
 15. SCOPE OF OPERATIVE MEDIASTINAL LYMPH NODE ASSESSMENT:			
1419      HIGHEST MEDIASTINAL (level 1)			
1419.1      UPPER PARATRACHEAL  (level 2)			
1419.2      PREVASCULAR AND RETROTRACHEAL                                                                       (level 3)			
1419.3      LOWER PARATRACHEAL  (level 4)			
1419.8      PULMONARY LIGAMENT  (level 9)			
1430 16. HCT (HEMOCRIT) VALUES BEFORE                                                     TRANSFUSION..................			
1420 17. TOTAL PERI-OPERATIVE BLOOD                                                       REPLACEMENT..................			
1421 18. PERI-OPERATIVE DEATH..........			
 FIRST COURSE OF TREATMENT - RADIATION THERAPY			
442 19. REGIONAL DOSE (cGy)...........			
56 20. NUMBER OF TREATMENTS TO THIS                                                     VOLUME.......................			
363 21. REGIONAL TREATMENT MODALITY...			
51.3 22. RADIATION/SURGERY SEQUENCE....			
1422 23. BOOST DOSE (cGy)..............			
127 24. INTENT OF RADIATION TREATMENT.			
75 25. REASON FOR NO RADIATION.......			
 26. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:			
1424 27. CHEMOTHERAPEUTIC TOXICITY.....			
1425 28. CHEMOTHERAPY/SURGERY SEQUENCE.			
 Do not answer data items 15-18.			
 Proceed to data item 19.			
 19. REGIONAL DOSE (cGy)...........: 			
 20. NUMBER OF TREATMENTS TO THIS			
 21. REGIONAL TREATMENT MODALITY...: 			
 22. RADIATION/SURGERY SEQUENCE....: 			
 23. BOOST DOSE (cGy)..............: Not administered			
 24. INTENT OF RADIATION TREATMENT.: 			
 25. REASON FOR NO RADIATION.......: 			
 Do not answer data items 26-28.			
 Proceed to data item 29.			
      COMPLICATION #1 may not be blank			
81 30. INITIALS OF CASE ABSTRACTOR...			
90 31. DATE CASE WAS ABSTRACTED......			
 2. DURATION OF TOBACCO USE.......: 			
 3. PERSONAL HISTORY OF OTHER			
 4. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:			
     SHORTNESS OF BREATH..........: 			
     PALPABLE LYMPH NODES.........: 			
 5. SCREENING FOR HIGH RISK/ASYMPTOMATIC PRESENTATION:			
     CT SCAN......................: 			
 6. INITIAL DIAGNOSTIC STUDIES (PRE-THERAPY):			
     HISTORY AND PHYSICAL.........: 			
     THOROCOTOMY/OPEN BIOSPY......: 			
Print Lung (NSCLC) PCE			
TUMOR EVALUATION			
 7. PULMONARY FUNCTION TESTS:			
     FVC (forced vital capacity)..: 			
     FEV (forced expiratory vol)..: 			
 8. LIVER FUNCTION TESTS..........: 			
 9. RADIOLOGICAL EVALUATION:			
     BONE SCAN....................: 			
      VASCULAR INVASION...........: 			
      MEDIASTINAL LYMPH NODES.....: 			
      SIZE OF DOMINANT TUMOR (mm).: 			
      NUMBER OF TUMORS............: 			
      EVIDENCE OF METASTASIS......: 			
     MRI SCAN OF CHEST............: 			
     MRI SCAN OF BRAIN............: 			
     X-RAY OF CHEST...............: 			
10. PRE-OP LYMPH NODE MAPPING:			
     HIGHEST MEDIASTINAL (level 1): 			
     UPPER PARATRACHEAL  (level 2): 			
     PREVASCULAR AND RETROTRACHEAL			
     LOWER PARATRACHEAL  (level 4): 			
     PULMONARY LIGAMENT  (level 9): 			
11. DATE OF FIRST TISSUE DIAGNOSIS: 			
12. DISTANCE IN MILLIMETERS TO CLOSEST MARGIN:			
13. FROZEN SECTION................: 			
     CHEST WALL...................: 			
15. SCOPE OF OPERATIVE MEDIASTINAL LYMPH NODE ASSESSMENT:			
16. HCT (HEMATOCRIT) VALUES BEFORE			
17. TOTAL PERI-OPERATIVE BLOOD			
18. PERI-OPERATIVE DEATH..........: 			
19. REGIONAL DOSE (cGy)...........: 			
20. NUMBER OF TREATMENTS TO THIS			
21. REGIONAL TREATMENT MODALITY...: 			
22. RADIATION/SURGERY SEQUENCE....: 			
23. BOOST DOSE (cGy)..............: 			
24. INTENT OF RADIATION TREATMENT.: 			
25. REASON FOR NO RADIATION.......: 			
26. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:			
27. CHEMOTHERAPEUTIC TOXICITY.....: 			
28. CHEMOTHERAPY/SURGERY SEQUENCE.: 			
     COMPLICATION #1..............: 000.00 No complications			
29. INITIALS OF CASE ABSTRACTOR...: 			
30. DATE CASE WAS ABSTRACTED......: 			
The Class of Case is not 0, 1, 2 or 6.			
The BEHAVIOR is not 2 (melanoma in situ) or 3 (malignant).			
9:Print Melanoma PCE			
This primary does not satisfy the Melanoma PCE eligibility criteria:			
1999 Patient Care Evaluation Study of Melanoma			
10. PERSONAL HISTORY OF MELANOMA			
11. PERSONAL HISTORY OF OTHER CANCER			
12. PREGNANCY AT INITIAL DX			
13. EXOGENOUS HORMONES			
  1. INSTITUTION ID NUMBER........: 			
  2. ACCESSION NUMBER.............: 			
  3. SEQUENCE NUMBER..............: 			
9  4. POSTAL CODE AT DIAGNOSIS.....			
  5. DATE OF BIRTH................: 			
9  7. SPANISH ORIGIN...............			
18  9. PRIMARY PAYER AT DIAGNOSIS...			
1100 10. PERSONAL HISTORY OF MELANOMA.			
1101 11. PERSONAL HISTORY OF OTHER CA.//			
      1ST SITE CODE...............: C88.8			
      DATE DIAGNOSED..............: 88/8888			
      2ND SITE CODE...............: C88.8			
      1ST SITE CODE...............: C99.9			
      DATE DIAGNOSED..............: 99/9999			
      2ND SITE CODE...............: C99.9			
1102      1ST SITE CODE...............//			
1103      DATE DIAGNOSED..............//			
1104      2ND SITE CODE...............//			
1105      DATE DIAGNOSED..............//			
 PREGNANCY AND HORMONES			
 12. PREGNANCY AT INITIAL DX......: NA, male			
 13. EXOGENOUS HORMONES...........: NA, male patient			
1106 12. PREGNANCY AT INITIAL DX......			
1107 13. EXOGENOUS HORMONES...........			
14. CLASS OF CASE			
15. DATE OF INITIAL DIAGNOSIS			
16. PRIMARY SITE (ICD-O-2)			
17. LOCATION OF DISEASE PRESENTATION			
20. BEHAVIOR CODE(ICD-O-2)			
20. BEHAVIOR CODE (ICD-O-2)			
 14. CLASS OF CASE................: 			
 15. DATE OF INITIAL DIAGNOSIS....: 			
 16. PRIMARY SITE (ICD-O-2).......: 			
 17. LOC OF DISEASE PRESENTATION..: NA, primary site known			
1108 17. LOC OF DISEASE PRESENTATION..			
 20. BEHAVIOR CODE (ICD-O-2)......: 			
26 22. DIAGNOSTIC CONFIRMATION......			
23. SIZE OF TUMOR (MELANOMA)			
26. EXTRANODAL EXTENSION			
28. NUMBER OF SATELLITE NODULES			
29. LOCATION OF IN-TRANSIT NODULES			
31. CLARK'S LEVEL OF INVASION			
32. ANGIOLYMPHATIC INVASION			
33. PERINEURAL INVASION			
34. GENERAL SUMMARY STAGE			
35. AJCC CLINICAL STAGE (cTNM)			
37. CLINICALLY AMELANOTIC			
38. AJCC PATHOLOGIC STAGE (pTNM)			
39. STAGED BY			
 TABLE III- EXTENT OF DISEASE AND AJCC STAGE			
1132 23. SIZE OF TUMOR (MELANOMA).....			
33 24. REGIONAL NODES EXAMINED......			
32 25. REGIONAL NODES POSITIVE......			
1110 26. EXTRANODAL EXTENSION.........			
 SATELLITE NODULES OF SKIN OR SUBCUTANEOUS TISSUE			
 28. NUMBER OF SATELLITE NODES....: No satellite nodules			
 28. NUMBER OF SATELLITE NODES....: NA, non-cutaneous melanoma			
 28. NUMBER OF SATELLITE NODES....: Unknown			
1112 28. NUMBER OF SATELLITE NODULES..			
1113 29. LOC OF IN-TRANSIT NODULES....			
 31. CLARK'S LEVEL OF INVASION....: NA, primary site unknown			
1115 31. CLARK'S LEVEL OF INVASION....			
 32. ANGIOLYMPHATIC INVASION......: NA, site unknown or ocular			
1116 32. ANGIOLYMPHATIC INVASION......			
 33. PERINEURAL INVASION..........: NA, site unknown or ocular			
1117 33. PERINEURAL INVASION..........			
35 34. GENERAL SUMMARY STAGE........			
 35. AJCC CLINICAL STAGE (cTNM):			
 36. ULCERATION,,,,,,,,,..........: NA, site unknown or ocular			
 37. CLINICALLY AMELANOTIC........: NA, site unknown or ocular			
1119 37. CLINICALLY AMELANOTIC........			
 38. AJCC PATHOLOGIC STAGE (pTNM):			
 39. STAGED BY:			
19     CLINICAL STAGE...............			
89     PATHOLOGIC STAGE.............			
SENTINEL NODES			
 TABLE IV - FIRST COURSE OF TREATMENT			
346 40. PROTOCOL ELIGIBILITY STATUS...			
 41. PROTOCOL PARTICIPATION........: Not on/NA			
 41. PROTOCOL PARTICIPATION........: Unknown			
560 41. PROTOCOL PARTICIPATION........			
 42. DATE OF FIRST COURSE TREATMENT: 			
 43. DATE OF NON CA-DIR SURGERY....: 			
 44. NON CANCER-DIRECTED SURGERY...: 			
1109 45. TYPE OF BIOPSY................			
 46. DATE OF CANCER-DIR SURGERY....: 			
 47. SURGICAL APPROACH.............: 			
 48. SURGERY OF PRIMARY SITE.......: 			
 49. SURGICAL MARGINS..............: 			
 50. DISTANCE FROM TUMOR TO EDGE OF                                                  SPECIMEN......................: 998  NA, surgery not performed			
1120 50. DISTANCE FROM TUMOR TO EDGE OF                                                  SPECIMEN......................			
 51. SCOPE OF LYMPH NODE SURGERY...: 			
 52. NUMBER OF LYMPH NODES REMOVED.: 			
 53. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),			
 55. SURGICAL CLOSURE..............: NA, surgery not performed			
 55. SURGICAL CLOSURE..............: Unknown			
1121 55. SURGICAL CLOSURE..............			
 56. REASON FOR NO SURGERY.........: 			
 57. PRE-OP LYMPHOSCINTIGRAPHY.....: NA, ocular site			
1122 57. PRE-OP LYMPHOSCINTIGRAPHY.....			
 58. SENTINEL NODES DETECTED BY....: NA, not done, ocular site			
 59. SENTINEL NODE BIOPSY..........: NA, not done, ocular site			
 60. SENTINEL NODES EXAMINED.......: NA, not done, ocular site			
 58. SENTINEL NODES DETECTED BY....: Unknown			
 59. SENTINEL NODE BIOPSY..........: Unknown			
 60. SENTINEL NODES EXAMINED.......: Unknown			
1123 58. SENTINEL NODES DETECTED BY....			
943 59. SENTINEL NODE BIOPSY..........			
1124 60. SENTINEL NODES EXAMINED.......			
 61. SENTINEL NODES POSITIVE.......: NA, not done, no exam, ocular site			
 62. HOW WAS SENTINEL NODE                                                           PATHOLOGICALLY EXAMINED.......: NA, not done, ocular site			
 61. SENTINEL NODES POSITIVE.......: Unknown			
1125 61. SENTINEL NODES POSITIVE.......			
1126 62. HOW WAS SENTINEL NODE                                                           PATHOLOGICALLY EXAMINED.......			
 63. IF SENTINEL NODE(S) POSITIVE:			
     WAS COMPLETE LYMPH NODE                                                         DISSECTION PERFORMED..........: NA, not done, no + nodes, ocular site			
     NUMBER OF BASINS DETECTED.....: NA, not done, no + nodes, ocular site			
     NUMBER OF BASINS POSITIVE.....: NA, not done, no basins dissected, ocular			
     NUMBER OF BASINS DETECTED.....: Unknown			
     NUMBER OF BASINS POSITIVE.....: Unknown			
1127     WAS COMPLETE LYMPH  NODE                                                        DISSECTION PERFORMED..........			
     NUMBER OF BASINS DETECTED....: NA, not done, no + nodes, ocular site			
     NUMBER OF BASINS POSITIVE....: NA, not done, no basins dissected, ocular			
     NUMBER OF BASINS DETECTED....: Unknown			
     NUMBER OF BASINS POSITIVE....: Unknown			
1128     NUMBER OF BASINS DETECTED.....			
1129     NUMBER OF BASINS POSITIVE.....			
 64. DATE RADIATION STARTED........: 			
 65. RADIATION THERAPY.............: 			
 66. REASON FOR NO RADIATION.......: 			
 67. DATE CHEMOTHERAPY STARTED.....: 			
 69. INTRAVENOUS THERAPY...........: NA, chemotherapy not administered			
 69. INTRAVENOUS THERAPY...........: Unknown if administered			
1130 69. INTRAVENOUS THERAPY...........			
 70. DATE HORMONE THERAPY STARTED..: 			
 71. HORMONE THERAPY...............: 			
 72. DATE IMMUNOTHERAPY STARTED....: 			
 74. IMMUNOTHERAPEUTIC AGENTS ADMINISTERED:			
     VACCINE THERAPY...............: NA			
     GENE THERAPY..................: NA			
     COLONY STIMULATING FACTORS....: NA			
     OTHER GIVEN, TYPE UNKNOWN.....: NA			
     VACCINE THERAPY...............: Unknown			
     GENE THERAPY..................: Unknown			
     COLONY STIMULATING FACTORS....: Unknown			
     OTHER GIVEN, TYPE UNKNOWN.....: Unknown			
884     VACCINE THERAPY...............			
1131     GENE THERAPY..................			
559     COLONY STIMULATING FACTORS....			
386     OTHER GIVEN, TYPE UNKNOWN.....			
 75. DATE OTHER TREATMENT STARTED..: 			
 76. OTHER TREATMENT...............: 			
77. DATE OF FIRST RECURRENCE			
78. TYPE OF FIRST RECURRENCE			
79. OTHER TYPE OF FIRST RECURRENCE			
77. TYPE OF FIRST RECURRENCE			
78. DATE OF FIRST RECURRENCE			
 TABLE V - FIRST RECURRENCE			
70 77. DATE OF FIRST RECURRENCE......			
71 78. TYPE OF FIRST RECURRENCE......			
71.4 79. OTHER TYPE OF 1ST RECURRENCE..			
80. DATE OF LAST CONTACT OR DEATH			
81. VITAL STATUS			
82. CANCER STATUS			
 TABLE VI - STATUS AT LAST CONTACT			
 80. DATE OF LAST CONTACT OR DEATH.: 			
15 81. VITAL STATUS..................			
 82. CANCER STATUS.................: 			
83. COMPLETED BY			
84. REVIEWED BY CANCER COMMITTEE			
 TABLE VII - OTHER INFORMATION			
81 83. COMPLETED BY..................			
82 84. REVIEWED BY CANCER COMMITTEE..			
 1. INSTITUTION ID NUMBER...........: 			
 2. ACCESSION NUMBER................: 			
 3. SEQUENCE NUMBER.................: 			
 4. POSTAL CODE AT DIAGNOSIS........: 			
 5. DATE OF BIRTH...................: 			
 7. SPANISH ORIGIN..................: 			
 9. PRIMARY PAYER AT DIAGNOSIS......: 			
10. PERSONAL HISTORY OF MELANOMA....: 			
11. PERSONAL HISTORY OF OTHER CA....: 			
     1ST SITE CODE..................: 			
     DATE DIAGNOSED.................: 			
     2ND SITE CODE..................: 			
    PREGNANCY AND HORMONES			
12. PREGNANCY AT INITIAL DX.........: 			
13. EXOGENOUS HORMONES..............: 			
14. CLASS OF CASE...................: 			
15. DATE OF INITIAL DIAGNOSIS.......: 			
16. PRIMARY SITE (ICD-O-2)..........: 			
17. LOC OF DISEASE PRESENTATION.....: 			
20. BEHAVIOR CODE (ICD-O-2).........: 			
22. DIAGNOSTIC CONFIRMATION.........: 			
Print Melanoma PCE			
 1999 Patient Care Evaluation Study of Melanoma			
TABLE III - EXTENT AND STAGE OF DISEASE			
23. SIZE OF TUMOR (mm)..............: 			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
